Insite Vision Inc (INSV) 0.3410 $INSV Eye Infections

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Insite Vision Inc (INSV) 0.3410 $INSV

Eye Infections Global Clinical Trials Review, H2, 2015
M2 - Thu Sep 10, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/376x9w/eye_infections) has announced the addition of the "Eye Infections Global Clinical Trials Review, H2, 2015" report to their offering. This clinical trial report provides an overview of Eye Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Eye Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Reasons to Buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned - Ajanta Pharma - Alcon - Allergan - Dompe Farmaceutici - InSite Vision - Laboratoires Thea - Merck & Co. - Novartis - SIFI - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/37...infections
AGN: 295.24 (+1.64), MRK: 52.09 (-0.63), VRX.TO: 298.92 (-3.40), NVS: 96.55 (+0.28)

Is Another Amendment of QLT-InSite Vision Deal Coming Up?
Zacks Equity Research - Zacks Investment Research - Tue Sep 08, 3:25PM CDT
InSite Vision Inc. (INSV), which is set to be acquired by QLT Inc. (QLTI), announced that it has received a superior unsolicited offer from a global pharmaceutical company.
QLTI: 3.44 (unch), GILD: 109.63 (+2.38), REGN: 533.30 (+2.08)

QLT Provides Additional Update on Its Proposed Acquisition of InSite Vision Incorporated
GlobeNewswire - Fri Sep 04, 8:01PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" announces that it has been advised by InSite Vision Incorporated ("InSite" that the board of directors of InSite has determined, in good faith and after consultation with its independent financial and legal advisors, that the second unsolicited offer, as announced in QLT's press release on September 3, 2015, from the multi-national pharmaceutical company (the "Bidder" to acquire all of the issued and outstanding shares of InSite (the "New Proposal" constitutes a "Company Superior Proposal", as defined in the Amended and Restated Agreement and Plan of Merger, dated June 8, 2015, by and among Insite, QLT and Isotope Acquisition Corp., as amended and restated on July 16, 2015 and August 26, 2015 (the "Amended and Restated Merger Agreement" .
QLTI: 3.44 (unch), QLT.TO: 4.58 (+0.03)

InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a "Company Superior Proposal"
Business Wire - Fri Sep 04, 4:49PM CDT
InSite Vision Inc. (OTCBB:INSV) today announced that InSite's Board of Directors has determined that the previously announced unsolicited offer from a global pharmaceutical company (the "Bidder" to acquire all outstanding shares of InSite Vision common stock at $0.35 per share in an all-cash transaction constitutes a "Company Superior Proposal" as defined in InSite's previously announced definitive agreement with QLT Inc. dated as of August 26, 2015 (NASDAQ:QLTI) (TSX:QLT).
QLTI: 3.44 (unch), QLT.TO: 4.58 (+0.03)

QLT Provides Further Update on Its Proposed Acquisition of InSite Vision Incorporated
GlobeNewswire - Thu Sep 03, 5:35PM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" announces that it has been advised by InSite Vision Incorporated ("InSite" that InSite has received a second unsolicited offer from the multi-national pharmaceutical company which initially made an unsolicited offer, as announced in QLT's press release on August 10, 2015, to acquire all of the issued and outstanding shares of InSite (the "New Proposal" . The New Proposal is only subject to due diligence regarding the recently filed BromSite patent lawsuit. InSite has further advised QLT that the board of directors of InSite, in consultation with its financial and legal advisors, will carefully review all aspects of the New Proposal, and has not changed its recommendation with respect to the proposed merger with QLT pursuant to the Amended and Restated Agreement and Plan of Merger, dated June 8, 2015, by and among InSite, QLT and Isotope Acquisition Corp., as amended and restated on July 16, 2015 and August 26, 2015 (the "Amended and Restated Merger Agreement" . The Amended and Restated Merger Agreement continues in full force and effect.
QLTI: 3.44 (unch), QLT.TO: 4.58 (+0.03)

InSite Vision Receives Second Unsolicited Acquisition Proposal for $0.35 per Share From a Global Pharmaceutical Company
Business Wire - Thu Sep 03, 3:12PM CDT
InSite Vision Inc. (OTCBB:INSV) today announced that the Company has received a second unsolicited proposal from a global pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at an increased price of $0.35 per share in cash. The proposal is only subject to due diligence regarding the recently filed BromSite(TM) patent lawsuit. InSite Vision believes the lawsuit is without merit.
QLTI: 3.44 (unch)

InSite Vision Announces New Date for Special Stockholder Meeting
Business Wire - Wed Sep 02, 5:25PM CDT
InSite Vision Incorporated (OTCBB:INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the company's Special Meeting of Stockholders to vote on certain matters in connection with the transaction with QLT Inc., including a proposal to adopt a Second Amended and Restated Agreement and Plan of Merger, will now be held at 10:00 a.m. Pacific Time on October 9, 2015, for stockholders of record on September 8, 2015. InSite Vision had previously announced that the Special Meeting would be held on September 30, 2015. The Special Meeting will be held at InSite Vision's headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail the definitive proxy statement for the Special Meeting in early September 2015.
QLTI: 3.44 (unch)

InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit
Business Wire - Wed Sep 02, 3:05PM CDT
InSite Vision Inc. (OTCBB: INSV) today announced that Johnson Matthey Pharmaceutical Materials, Inc. (Johnson Matthey) has filed a patent lawsuit in the United States District Court for the District of Delaware in connection with activities relating to InSite Vision's New Drug Application (NDA) seeking commercial approval from the U.S. Food and Drug Administration (FDA) for BromSite(TM) (0.075% bromfenac) for the treatment of inflammation and prevention of pain associated with cataract surgery.

QLT Provides Update on Its Proposed Acquisition of InSite Vision Incorporated
GlobeNewswire - Fri Aug 21, 7:39AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" announces that it has been advised by InSite Vision Incorporated ("InSite" that the board of directors of InSite has determined in good faith after consultation with its independent financial and legal advisors that the previously announced unsolicited offer from a multi-national pharmaceutical company (the "Bidder" to acquire all of the issued and outstanding shares of InSite (the "Proposal" constitutes a "Company Superior Proposal" as defined in the Agreement and Plan of Merger, dated June 8, 2015, by and among Insite, QLT and Isotope Acquisition Corp., as amended and restated (the "Merger Agreement" . InSite has further advised QLT that InSite intends, subject to QLT's right to match the Proposal, to terminate the Merger Agreement and enter into an agreement with the Bidder to implement the Proposal.
QLTI: 3.44 (unch), QLT.TO: 4.58 (+0.03)

InSite Vision Determines that an Unsolicited Offer from a Multi-National Pharmaceutical Company to Acquire InSite for $0.25 in Cash Constitutes a "Company Superior Proposal"
Business Wire - Fri Aug 21, 7:30AM CDT
InSite Vision Inc. (OTCBB:INSV) today announced that InSite's Board of Directors determined that the previously announced unsolicited offer from a multi-national pharmaceutical company (the "Bidder" to acquire InSite for $0.25 per share in an all-cash transaction constitutes a "Company Superior Proposal" as defined in InSite's previously announced definitive agreement with QLT Inc. dated as of June 8, 2015, as amended (NASDAQ: QLTI) (TSX: QLT). Under the terms of the QLT merger agreement, QLT would acquire InSite in an all-stock transaction in which shareholders of InSite will receive 0.048 QLT shares for each InSite share they hold.
QLTI: 3.44 (unch), QLT.TO: 4.58 (+0.03)

Blepharitis Pipeline Review, H2 2015 - Reviews Key Players Involved in the Therapeutics Development for Blepharitis
M2 - Wed Aug 19, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cb3rdq/blepharitis) has announced the addition of the "Blepharitis - Pipeline Review, H2 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Blepharitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Blepharitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Blepharitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Blepharitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned - Allergan Plc - Foamix Pharmaceuticals Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - NicOx S.A. For more information visit http://www.researchandmarkets.com/research/cb...lepharitis
AGN: 295.24 (+1.64), FOMX: 9.95 (-0.04)

InSite Vision Announces FDA Acceptance of NDA Filing for BromSite(TM) (0.075% bromfenac)
Business Wire - Mon Aug 17, 3:05PM CDT
--Marketing approval is being sought for use in treatment of inflammation and prevention of pain after cataract surgery

InSite Vision falls to net loss of USD6.6m for Q2 2015
M2 - Wed Aug 12, 5:29AM CDT
Ophthalmic company InSite Vision (Other OTC:INSV) stated on Tuesday that it recorded a net loss of USD6.6m (USD0.05 per share) for the quarter ended 30 June 2015.

InSite Vision Announces Date for Special Stockholder Meeting
Business Wire - Tue Aug 11, 6:58PM CDT
InSite Vision Incorporated (OTCBB:INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the company's Special Meeting of Stockholders to vote on certain matters in connection with the transaction with QLT Inc., including a proposal to adopt an Agreement and Plan of Merger, will be held at 10:00 a.m. Pacific Time on September 30, 2015, for stockholders of record on August 25, 2015. The Special Meeting will be held at InSite Vision's headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail the definitive proxy statement for the Special Meeting in early September 2015.
QLTI: 3.44 (unch)

InSite Reports Second Quarter 2015 Financial Results
Business Wire - Tue Aug 11, 3:05PM CDT
InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the quarter ended June 30, 2015. Revenues for the quarter ended June 30, 2015 were $0.4 million compared to $6.3 million for the same period in 2014; revenues in 2014 included a $6.0 million payment from Akorn, Inc. for an amendment to their AzaSite(R) license agreement (Akorn License). Net loss for the quarter ended June 30, 2015 was $6.6 million, or $0.05 per share, compared to net income of $37.1 million, or $0.28 per share, in the second quarter of 2014. In the second quarter of 2014, InSite recorded a gain of $36.0 million on the extinguishment of the AzaSite Notes. As of June 30, 2015, cash and cash equivalents totaled $1.8 million.
QLTI: 3.44 (unch), AKRX: 38.38 (+0.33)

QLT Provides Update on Merger With InSite Vision Incorporated
GlobeNewswire - Mon Aug 10, 7:39AM CDT
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT" or the "Company" announces that it has been advised by InSite Vision Incorporated ("InSite Vision" that InSite Vision has received an unsolicited offer from a multi-national pharmaceutical company to acquire all of the issued and outstanding shares of InSite Vision (the "Proposal" . InSite Vision has further advised QLT that the board of directors of InSite Vision is reviewing the Proposal, and has not changed its recommendation with respect to the proposed merger with QLT pursuant to the Agreement and Plan of Merger (the "Merger Agreement" among QLT, InSite Vision, and Isotope Acquisition Corp., dated June 8, 2015. The Merger Agreement continues in full force and effect.
QLTI: 3.44 (unch), QLT.TO: 4.58 (+0.03)

InSite Vision Receives Unsolicited Proposal from a Multi-National Pharmaceutical Company
Business Wire - Mon Aug 10, 7:30AM CDT
InSite Vision Inc. (OTCBB:INSV) today announced that the Company has received an unsolicited proposal from a multi-national pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at a price of $0.25 per share in cash. The proposal is non-binding and is subject to further due diligence.
QLTI: 3.44 (unch)

Qiagen Inks Molecular Diagnostics Partnership with Seegene - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 09, 1:20PM CDT
Qiagen N.V. (QGEN) recently inked a worldwide collaboration agreement with multiplex molecular technologies and multiplex clinical molecular diagnostics developer Seegene Inc.
ACHN: 7.77 (+0.04), AMAG: 53.00 (-4.65), QGEN: 26.68 (+0.24)

Cataract - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d86sd5/cataract) has announced the addition of the "Cataract - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - CalAsia Pharmaceuticals, Inc. - EyeGate Pharmaceuticals, Inc. - InSite Vision Incorporated - Laboratorios Sophia S.A. de C.V. - Laila Pharmaceuticals Pvt. Ltd. - Omeros Corporation - R-Tech Ueno, Ltd. For more information visit http://www.researchandmarkets.com/research/d86sd5/cataract
EYEG: 4.24 (-0.21), OMER: 14.12 (+0.33)

INSITE VISION INCORPORATED SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Wed Jun 17, 10:19AM CDT
Rigrodsky & Long, P.A.:
QLTI: 3.44 (unch)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 238

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 0

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 0

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading